Business
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel
About this update from Sab Biotherapeutics, Inc.
[{"type":"text","content":"SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today reported financial results for the third quarter ended September 30, 2022, and provided a company update. “We continue to utilize our capabilities and infrastructure to advance our development pipeline in immunotherapeutics directed at unmet medical needs in respiratory diseases and in gastrointestinal disease with our Clostridioides difficile (C. diff) program and have discovery programs in autoimmune disease and oncology. During the quarter we were able to show data that further validates our platform at targeted medical conferences. Additionally, we signed a contract manufacturing agreement with Emergent BioSolutions, one of the few companies experienced in both human and animal plasma fractionation and purification uniquely qualified to manufacture SAB’s novel fully-human polyclonal antibody products,” said Eddie J. Sullivan, Ph.D., Co-Founder, President, and Chief Executive Officer of SAB Biotherapeutics. Pipeline Updates and Anticipated Milestones SAB continues to execute on its strategy to build a proprietary immunology pipeline addressing respiratory and gastrointestinal diseases that disproportionately affect patients who are immunocompromised or have autoimmune disorders. Below are some key highlights and milestones from the quarter: During the quarter, the company presented an overview of its DiversitAb™ polyclonal platform and data on SAB-176 and SAB-185 at the 2022 Plasma Product Biotechnology Conference in Limassol, Cyprus. The data presented showed the benefits of fully-human polyclonal antibodies derived from SAB’s Transchromosomic (Tc) Bovine™ over plasma derived antibodies from humans. The SAB fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating viruses.The company also presented at a conference hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland. The data presented showed its fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly...